We could not find any results for:
Make sure your spelling is correct or try broadening your search.
BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer PR Newswire BERGEN, Norway, Aug. 22, 2023...
BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer PR Newswire BERGEN, Norway, Aug. 22, 2023...
BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue PR Newswire BERGEN, Norway, May 26, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR...
BerGenBio ASA: Proposed partially underwritten rights issue PR Newswire BERGEN, Norway, April 25, 2023 NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 46 | 46 | 46 | 483692 | 46 | DE |
4 | 0 | 0 | 46 | 46 | 46 | 86834 | 46 | DE |
12 | 0 | 0 | 46 | 46 | 46 | 57609 | 46 | DE |
26 | 0 | 0 | 46 | 46 | 46 | 304085 | 46 | DE |
52 | 0 | 0 | 46 | 46 | 46 | 289297 | 46 | DE |
156 | 0 | 0 | 46 | 46 | 46 | 115836 | 46 | DE |
260 | 0 | 0 | 46 | 46 | 46 | 86508 | 46 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions